| Followers | 0 |
| Posts | 1357 |
| Boards Moderated | 0 |
| Alias Born | 03/20/2022 |
Friday, August 19, 2022 12:24:19 AM
The fact that the company feels confident enough to approach the fda with the 210 data leads me to believe it was sufficient to achieve an endpt change.
This is based purely on logic sans any further info.
This is based purely on logic sans any further info.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
